Key Highlights
- MRNA closed up 6.69% at $242.08 on October 20, up 16.59% over the week and 52.87% over the month, with a market capitalization of about $96.85 billion.
- The stock closed at more than three times Citi's $80 price target, set on September 30.
- Second-quarter revenue was $145 million, against $142 million a year earlier.
- Cash and investments fell to $6.9 billion at June 30 from $7.5 billion at March 31 after a $950 million litigation settlement.
- Five-year melanoma data for intismeran showed a 49% reduction in the risk of recurrence or death.
What Are Investors Missing as Moderna Stock Climbs 17% in a Week to $242.08?
Moderna (NASDAQ:MRNA) closed up 6.69% at $242.08 on October 20 and is up 16.59% over the week and 52.87% over the past month. The market capitalization is about $96.85 billion. No company-specific announcement was identified for October 13 to 21, so the week's gain is best read as the latest leg of a rally that has been building for weeks rather than a reaction to one headline.
The stock closed at $203.21 on October 6, up 6.95% that day, when it was already up more than sixfold for the year. Its inclusion in the Nasdaq-100 index took effect before the open on October 9. On September 30, Citi downgraded the stock to Sell while raising its price target to $80 from $60, noting that shares had risen 222% since interim results from the INTerpath-001 cancer vaccine study. At $242.08, the stock closed at more than three times that target.
Management changes were announced in early October, with a returning executive taking a new chief operating officer role and the chief technical and quality officer retiring.
Which Pipeline Results Sit Behind the Moderna Rally, and Which Fell Short?
The FDA approved mRNA-1010, branded mFlusiva, as the first mRNA flu vaccine. Approval covers adults aged 50 to 64 on the basis of a Phase 3 study of 40,805 participants, and adults aged 65 and older under accelerated approval.
A combination flu and COVID vaccine, mRNA-1083, is approved in the European Union as mCombriax, and Moderna is awaiting FDA guidance on a United States refiling.
Results have been mixed. The norovirus candidate mRNA-1403 missed early-success criteria at its Phase 3 interim. Five-year Phase 2b data for the cancer vaccine intismeran in melanoma showed a 49% reduction in the risk of recurrence or death when added to an approved checkpoint inhibitor, and the Phase 3 melanoma study is fully enrolled.
Do Moderna's Second-Quarter Numbers Match a Price Above $240?
Second-quarter revenue was $145 million, compared with $142 million a year earlier. The net loss was $782 million, or $1.97 per share, against $2.13 per share a year earlier.
Cash and investments fell to $6.9 billion at June 30 from $7.5 billion at March 31, after a $950 million litigation settlement was paid in July. The revenue base remains small relative to the $96.85 billion market value.
Full-year guidance calls for revenue growth of up to 10% over 2025, cost of sales of about $1.7 billion including a $0.9 billion non-recurring litigation charge, and research and development of about $2.9 billion. Year-end cash is expected at $4.7 billion to $5.2 billion.
What Could the November 12 Analyst Day Add to the Moderna Story?
Moderna's next scheduled event is the November 12 analyst day, at which management can address guidance and the pipeline. The FDA response on the combination vaccine refiling is another item to track. The price sits well above the most recent reference point of Citi's $80 target.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...